Clinical Trials · NCT07563699
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Mapi Pharma Ltd.
- Enrollment
- 24
- Start date
- Aug 2026
- Locations
- 1 site, Israel
- Primary endpoint
- The rate of treatment-associated adverse events (AEs)